Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive data for ViroPharma hepatitis C drug
The preliminary data were produced from a dose range of 100mg BID to 1,000mg BID of HCV-796 dosed over a 14-day period in combination with pegylated interferon alfa-2b.
The preliminary data were produced from a dose range of 100mg BID to 1,000mg BID of HCV-796 dosed over a 14-day period in combination with pegylated interferon alfa-2b.
Patients in the study had suffered a second relapse with duration of second response less than six months, or had been refractory to two previous courses of induction
The committee recommended by a majority vote that the data presented by Adeza in its new drug application for Gestiva support efficacy in preventing preterm birth prior to
The regulation allows the conduct of research studies to test emergency treatments on patients with specific life-threatening medical conditions, such as head trauma, cardiac arrest and stroke, when
The company has selected these indications because high levels of the drug’s target are found in these cancers. AS1409 is a fusion protein with two components. It contains
The researchers found the risk of developing an enlarged prostate was 50% lower in NSAID users compared to non-users, and risk of developing moderate to severe urinary symptoms
Under the agreement, Stem Cell Therapeutics (SCT) will pay StemCells up-front and license maintenance fees, as well as milestone and royalty payments. The agreement also provides StemCells with
Under the terms of the settlement, Teva will stop selling its oxycodone products that contravene the OxyContin patent and Purdue Pharma will not pursue damages against Teva for
The company received the extended exclusivity after the FDA accepted for review a clinical package submitted by the company which contained data about the use of Colazal in
Epix submitted the appeal to the FDA’s Office of New Drugs (OND) on June 30, 2006 in response to two prior approvable letters for Vasovist. Epix were also